Week
52:
- Out of more than 200 patents and applications relating to lansoprazole,
no fewer than 13 to date have attracted term extension or supplementary
protection activity. This Takeda proton pump inhibitor, first
claimed in the mid-1980s in EP174726...
- A further notice reports an uncommon SPC event, the voluntary
surrender of an active SPC by the owner. In this case, Bristol-Myers
Squibb (BMS) is reported to have surrendered the SPC for nefazodone
hydrochloride (Serzone)...
- UK initial (“A0”) applications filed November 16th
- November 23rd 2005
|
Week
51:
- This week’s UK Patents and Designs Journal contains details
of the two SPC applications reported in the Current Patents Gazette
two weeks ago (Issue 0549). The first is to the University of
Missouri on EP201601 for Yttrium 90 glass microspheres...
- The entry into force of the SPC on EP184162 for tacrolimus (Prograf)
was also recorded in this weeks PDJ. SPCs have been granted to
Fujisawa (now Astellas Pharma) on this patent...
- The big story coming out of the US in the last week has been
the decision by a Federal Court in Delaware that upheld two key
Pfizer patents protecting atorvastatin, the active ingredient
in Lipitor...
- UK initial (“A0”) applications filed November 9th
- November 16th 2005
|
Week
50:
- The UK Patents and Design Journal this week mainly contains
details of Agrochemical SPCs being granted and coming into force.
The only pharmaceutical entry concerns the grant of a Certificate
to NPS Pharmaceuticals for cinacalcet...
- Protein Design Labs filed a further SPC application on EP451216
on December 8, 2005. This application, for omalizumab (Xolair),
is the fifth application on this patent...
- At their meeting on December 9th, the EU Council reached a “political
agreement” on the draft regulation on medicinal products
for paediatric use. This means that the proposal was not passed
on the first reading, but a “Common Position” was
reached...
- UK initial (“A0”) applications filed November 2nd
- November 8th 2005
|
Week
49:
- The UK Patents and Designs Journal (PDJ) this week reports the
grant of an SPC to Genentech for efalizumab (Raptiva)...
- The entry into force of the SPC for Amersham’s (GE Healthcare)
Omniscan (gadodiamide) is also recorded in the PDJ this week...
- Recently filed SPC applications that have not yet been reported
in the PDJ include one to the University of Missouri on EP201601
for Yttrium 90 glass microspheres...
- Another recent application was Pfizer’s third application
for veterinary antibiotic ceftiofur...
- Indian patents were in the news again this week, with the news
that Multinational Corporations that had filed Black box (or more
correctly, Mailbox) applications for Pharmaceutical products,
were being hit by a wave of oppositions by Indian companies...
- UK initial (“A0”) applications filed October 25th
- November 2nd 2005
|
Week
48:
- The two new SPC applications mentioned in last weeks Current
Patents Gazette are officially notified in the UK PDJ this week...
- Genentech’s application for an SPC on EP851925 for pegvisomant
is a more straightforward application which if granted should
expire November 2017, fifteen years after the first EU approval
date...
- Also reported in the PDJ is the expiry on November 6 of the
SPC for GSK’s calcium antagonist, lacidipine...
- The Japanese Gazette for November contained details of four
granted patent extensions for tacrolimus to Astellas Pharma KK.
Originally patented by Fujisawa...
- KuDOS Pharmaceuticals Ltd has filed an UK initial application
covering phthalazinone derivatives...
- UK initial (“A0”) applications filed October 19th
-October 25th 2005
|
Week
47:
- A month ago the Current Patents Gazette reported that UK PDJ
6075 incorrectly recorded SPC/GB99/004 on EP463756 for Pfizer’s
sildenafil (Viagra) as withdrawn...
- The entry into force on October 31 of the SPC for formestane,
which is approved for the treatment of breast cancer, is recorded
in this week’s PDJ...
- Also recorded in this week’s PDJ is the expiry on October
27 of the SPC for Pfizer’s antidepressant, sertraline (Zoloft)...
- Following a High Court ruling in December 2004, the PDJ reports
that Sankyo’s SPC on GB2093695 for the ivermectin + praziquantel
veterinary combination has been revoked...
- Two SPCs were added recently to the UK list of pending applications,
the first being filed by Genentech for pegvisomant with Chiron
filing an application for enfuvirtide...
- UK initial (“A0”) applications filed October 12th
- October 19th 2005
|
Week
46:
- As reported in last week’s Current Patents Gazette, GlaxoSmithKline
Biologicals have filed an SPC application on EP1240905 in the
UK for their Boostrix IPV vaccine...
- Also reported in the PDJ are three SPC grants including two
Plant Protection SPCs granted to BASF and Syngenta respectively...
- Entering into force recently was the SPC for liposomal daunorubicin.
This was granted to NeXstar Pharmaceuticals and extends the protection
on the product for around 4.5 years...
- At the opposite end of the SPC process, the SPC on Glaxo’s
salmeterol expired on October 25. This should mean a further decline
in sales revenue for salmeterol which achieved revenue of $651.3
million in 2004...
- Chiron also feature in the PDJ with notice being given that
two related patents (EP181160 and EP1245678) were referred to
the Patent Court on August 12, 2005 for revocation following opposition
by a number of competitors...
- On November 16th Roche and Gilead announced that they had resolved
their dispute over Tamiflu (oseltamivir), resulting in a “redefined”
agreement...
- Also announced recently was the UK House of Lords’ decision
on the GSK (formerly Beecham) patent for paroxetine methanesulfonate,
which it declared invalid, thus overturning the Court of Appeal
judgement and restoring the trial judge’s decision. Synthon
had challenged the Beecham patent claiming lack of novelty...
- UK initial (“A0”) applications filed October 5th
- October 12th 2005
|
Week
45:
- Although not yet reported in the UK Patents and Design Journal
(PDJ), GlaxoSmithKline Biologicals have filed an SPC application
on EP1240905 in the UK for their Boostrix IPV vaccine (also known
as Boostrix Polio or DTP + IPV)...
- The Japanese Gazette for October contained details of patent
extensions of almost four years awarded to Aventis Pharma SA on
JP2992540, which now expires in April 2019, for telithromycin...
- The PDJ this week reports the granting of an SPC to Roche Palo
Alto LLC for palonosetron on EP0430190, which expires November
2015. Helsinn Healthcare have developed palonosetron, marketed
as Aloxi or Onicit...
- UK initial (“A0”) applications filed September 28th
- October 5th 2005
|
Week
44:
- After last week’s glut of SPC information in the Patents
and Designs Journal, there are only 2 items in the current weeks
PDJ Proceedings. The entry into force on October 7, 2005 of the
SPC awarded to Teijin on EP177920 for tacalcitol...
- Also entering into force in October was the SPC awarded on EP177957
to Zymogenetics for becaplermin, which expires after the full
five years on October 9, 2010. Ortho-McNeil Pharmaceutical Inc...
- Sun Pharma subsidiary Caraco Pharamaceutical Labs has received
a favorable ruling in a US court regarding its plans to launch
a generic version of Johnson and Johnson’s painkiller Ultracet...
- Taiwan’s Health Minister has asked the country’s
Bureau of Intellectual Property Rights to request a “coercive
authorization” from Roche AG to allow the island to produce
the anti-bird flu drug Tamiflu...
- Illumina Inc has filed a request with the USPTO for Interference
with Stanford Univ’s US6858412 - “Direct multiplex
characterization of genomic DNA”...
- UK initial (“A0”) applications filed September 23rd
- September 30th 2005
|
Week
43:
- The UK Patents and Designs Journal contains a larger than normal
amount of SPC information this week, with nine grants and three
withdrawals reported...
- Pfizer’s application (in the name of GD Searle) on EP731795
for celecoxib was deemed withdrawn, as the difference between
the first approval and the filing dates...
- Novartis were granted over three years protection with an SPC
on EP564409 for anticancer drug imatinib...
- Protein Design Labs have obtained a certificate of 4.5 years
for trastuzumab on EP451216. SPCs have already been granted in
the UK on this patent for daclizumab, palivizumab and bevacizumab...
- Millennium Pharmaceuticals lost over two years on their SPC
for eptifibatide (Integrilin) when the Swiss approval date is
used rather than the centralised approval date of July 1999. Thus
means that the SPC on EP477295 for eptifibatide will now expire
February 2012...
|
Week
42:
- Three SPC grants were reported in the UK Patents and Designs
Journal (No. 6074) this week, a 2003 application for an agrochemical
product from Bayer Cropscience being the first one reported. GSK
(formerly The Wellcome Foundation) received a certificate of...
- Syngenta Ltd is the third company to receive the grant of an
SPC this week, but unusually for them, this is not for an agrochemical
product. The SPC granted on EP591275 is for nitisinone, which
has Orphan Drug status...
- Patent protection has been in the news this week due to the
media focus on avian flu and the question about the ability of
Roche to supply the sudden demand for its antiviral, Tamiflu (oseltamivir)...
- UK initial (“A0”) applications filed September 8th
- September 15th 2005
|
Week
41:
- In July 2004 (Current Patents Gazette 0428), we commented on
an SPC application by Novartis for eplerenone based on EP122232.
This was unusual in that the SPC application, filed 3 days before
the patent expiry...
- The grant of an SPC on EP654264 to Boehringer Ingelheim for
duloxetine was also reported in the PDJ, which is due to expire
August 10, 2019. Marketed as Yentreve or Ariclaim...
- Several interesting cases have been highlighted in Section A
this week. Lexicon Genetics, a biopharmaceutical company, has
published data on a series of small-molecule protein kinase inhibitors.
- Enigma Diagnostics Ltd has an initial UK patent application
entitled “Liquid transfer device”, and this follows
on from WO2005019836 concerned with apparatus for processing a
fluid sample...
- UK initial (“A0”) applications filed August 31st
- September 7th 2005
|
Week
40:
- The UK Patents and Designs Journal this week records details
of one SPC entering into force and two “withdrawn”
SPCs. Extended protection for Novartis’ antiviral famciclovir...
- Withdrawn applications for SPCs by Roche on EP809996 for their
Pegasys (peginterferon alpha 2A) product and Yeda on EP762888
for Copaxone...
- TransForm Pharmaceuticals, a J&J subsidiary, raises some
interesting questions this week with a couple of formulation cases
relating to “conazole” antifungals and MRP1 inhibitors...
- UK initial (“A0”) applications filed August 24th
- August 31th 2005
|
Week
39:
- The grant of an SPC to Duke University for enfuvirtide, Roche’s
anti-HIV fusion inhibitor Fuzeon...
- The Hungarian gazette for September contains details of the
two SPC grants reported in the 2005-36 issue of the Current Patents
Gazette to Schering for Desloratidine and to Merz Pharma for memantine...
- The September Japanese gazette gave details of 14 granted extensions
on 13 patents of which 6 related to pharmaceuticals. Additionally,
14 new extension applications were reported on 11 patents, all
of which had pharmaceutical relevance...
- UK initial (“A0”) applications filed August 19th
August 26th 2005
|
Week
38:
- The UK Patents and Design Journal reports this week the grant
of an SPC for the full five years for Eli Lilly’s pemetrexed
on the European product patent...
- US patents protecting GlaxoSmithKline’s anti-HIV treatment
Retrovir (zidovudine) expired on 17th September...
- Akzo Nobel’s human healthcare business, Organon, has entered
into a non-binding letter of intent with Cincinnati’s Duramed
Pharmaceuticals (a Barr subsidiary) to settle the pending patent
litigation concerning...
- Aventis Pharmaceuticals and Albany Molecular Research have filed
a motion for a preliminary injunction or expedited trial in the
United States District Court for the District of New Jersey to
prevent Barr Pharmaceuticals and Teva Pharmaceuticals from marketing
their generic versions of Allegra. (fexofenadine hydrochloride)...
- On September 7th the proposed new European paediatric medicines
legislation came closer to implementation when the European Parliament
approved the Commission proposal - with a number of amendments...
- UK initial (“A0”) applications filed August 12th
- August 19th 2005
|
Week
37:
- This week’s Patents and Designs Journal (PDJ) from the
UK Patent Office contains a total of nine notices relating to
Supplementary Protection Certificates (SPCs), including formal
publication of the two new Teva /Technion rasagiline applications...
- Of the newly granted SPCs reported above, it is those for trastuzumab
and bevacizumab that hold the greatest interest in commercial
terms, not least because they are about to become head-to-head
competitors in the same anticancer monoclonal antibody franchise...
- A further new application, dated August 26th 2005, has now been
posted on the UK Patent Office’s website, bringing the total
for the year so far to 44. If this rate of filing continues, there
could be almost 70 UK SPC applications filed by the end of the
year,...
- UK initial (“A0”) applications filed August 4th
- August 11th 2005
|
Week
36:
- Three Hungarian SPCs noted in the 0531 issue of the Current
Patents Gazette as being granted, but not yet published, were
duly published in the HPO’s August Gazette. These were to
ICOS Corp for tadalafil, Aventis Pharma for insulin glargine and
H. Lundbeck for escitalopram oxalate...
- We also note the grant of two SPCs, both for five years, which
are due to be published in the September Hungarian Gazette. The
first is to Merz Pharma GmbH for memantine (a treatment for cerebral
ischemia)...
- This week’s UK PDJ reports the expiry of two SPCs: Roche’s
antifungal agent amorolfine,...
- Also reported in the PDJ is the rejection of the SPC application
by Knoll AG (now part of Abbott) for sibutramine hydrochloride
monohydrate...
- Note: Article 3 (c) of the SPC regulations requires that “the
product has not already been the subject of a certificate”.
Whilst this was undoubtedly the case initially (both applications
were submitted at the same time) this proviso was not met...
- UK initial (“A0”) applications filed July 28th -
August 3rd 2005
|
Week
35:
- For the first time this year, the Japanese Patent Gazette contained
no details of any patent extension applications or grants in August.
However, the UK Patents and Design Journal...
- Also noted this week, but not yet published in the PDJ were
joint SPC applications by Teva Pharmaceuticals and Technion Research
and Development Foundation. Two applications were submitted for
rasagiline or its salts...
- The PDJ also reports the expiry on August 5th of the SPCs for
Roche’s ACE inhibitor cilazapril (Inhibase) and Novartis’
terbinafine (Lamisil)...
- Dr Robet Holton, a Professor at Florida State University and
founder of Taxolog, is named as the sole inventor on WO2005079319,
published this week. The application claims MST-997...
- Pro-Cure Therapeutics Ltd, a Yorkshire based company, has filed
five GB applications, all of which were published in the PDJ this
week. The applications relate to stem cell markers...
- UK initial (“A0”) applications filed July 21st -
July 28th 2005
|
Week
34:
- The UK Patent Office has recently announced a change in practice
when deciding whether or not applications contain a patentable
invention. The change, based on a series of judgments that include
one in 1997 relating to Biogen Inc and Medeva plc...
- Halocarbon Products Corporation of New Jersey, in the course
of claiming an intermediate for the anesthetic sevoflurane, seems
to have come up with a new form of disclaimer on the front page
of one of this week’s PCT applications...
- The entry into force of the SPC for GlaxoSmithKline’s
anti-migraine treatment, sumatriptan, on August 1st is recorded
in the UK PDJ this week. This gives GSK a further 9 months protection
on...
- Also recorded in the PDJ was the entry into force on July 31st
of TAP’s SPC protecting lansoprazole on EP174726, which
expires December 10th, 2005. Lansoprazole (Zoton; Lanzor; Takepron;
Prevacid; Naprapac) is a proton pump inhibitor...
- UK initial (“A0”) applications filed July 14th -
July 21st 2005
|
Week
33:
- The UK Patents and Design Journal (PDJ) this week reports the
lodging of the SPC application by Novartis on EP900210 for atazanavir
sulphate (Reyataz).
- Also reported in the PDJ this week is the entry into force on
25th July, of the SPC protecting Chugai’s lenograstim, which
is co-marketed with Sanofi-Aventis in a number of markets outside
the USA. Available as an injectable formulation, lenograstim is
indicated to lessen neutropenia associated with myelosuppressive
chemotherapy, bone marrow transplants, and severe chronic neutropenia.
- Merck, once the world’s largest drugs manufacturer, was
forced to pay damages of $250 million to an American widow this
week. The case rested on her husband’s use of Vioxx (rofecoxib),
a COX-2 inhibitor.
- GSK’s blockbuster drug, Seroxat, has also been rocked
by allegations this week. Seroxat (paroxetine) is one of the UK's
most widely prescribed anti-depressant drugs, but a recent study
has shown that it has been linked to a seven-fold increase in
suicide attempts.
- The prices and market value of generic ceftriaxone products
have dropped by 40 per cent in the US following the patent expiry
on Rocephin (US5089490), which was marketed by patent holder Roche
in the US.
|
Week
32:
- The entry into force on July 17th of the SPC protecting mivacurium
chloride (Mivacron) is recorded in this week’s UK Patents
and Design Journal (The PDJ). Mivacron was originally developed
by The Wellcome Foundation (now GSK) and the Massachusetts General
Hospital Corporation.
- Also recorded in this week’s PDJ is the expiry of Bracco’s
SPC for iomeprol on July 17th. According to our Investigational
Drugs database (IDdb), iomeprol is used as a contrast agent in
brain and liver imaging and cardio-angiography.
- Several new applications have been filed recently, with Syngenta,
Kumiaia and Ishihara Sangyo all filing applications for SPCs on
Agrochemicals. Gilead Sciences have requested an SPC on EP915894
for tenofovir disoproxil in combination with another pharmaceutical
ingredient, in particular, emtricitabine.
- It has been reported this week that Genzyme and Biogen Idec
have settled a lawsuit against Columbia University relating to
drug producing technology developed by the University. The technology
developed by professor Richard Axel is a technique for the introduction
of DNA into eukaryotic cells.
|
Week
31:
- The Japanese gazette containing the July patent extensions was
received this week and contains details of six extensions granted.
Sankyo KK and Ube Industries were granted three extensions...
- Notification of the grant of four SPCs were reported in this
week's UK PDJ. These included the grant of 2005 applications to
Bayer Cropscience for fluoxastrobin and to Merck Frosst Canada...
- Only one new SPC application was reported in July by the Hungarian
Patent Office, with Genentech filing an SPC application for bevacizumab...
- Aventis had gained transitional protection on HU210800 based
on EP368187 which would normally expire on November 6, 2009. An
SPC has now been granted for insulin glargin...
- UK initial (“A0”) applications filed June 23rd -
June 30th 2005
|
Week
30:
- This weeks UK Patent and Designs Journal contains details of
almost every possible SPC event, except for new filings. Novo
Nordisk and Chiron have withdrawn their request for an SPC for
Recombinant human factor VIII as present in Baxter’s Advate...
- SPCs were granted to Biogen and Health Research International
for bivalirudin...
- Entering into force in the first week of July were the SPCs
for Novartis’ molgramostim, which expires October 2007 and
Genentech’s Recombinant TNF-alfa product (tasonermin)...
- Although not yet reported in the PDJ, Novartis have filed an
application for an SPC on atazanavir sulphate (Reyataz)...
- It was announced this week that two of GlaxoSmithKline’s
US patents protecting the use of ondansetron have been ruled valid
and are infringed by Kali Laboratories (a subsidiary of Par Pharmaceutical
Companies)...
- UK initial (“A0”) applications filed June 16th -
June 22nd 2005
|
Week
29:
- The UK Patents and Design Journal (PDJ No. 6061) contained details
of only two SPC events this week, namely the expiry of Eli Lilly’s
SPC for their veterinary antibiotic, tilmicosin on June 24 and
Novartis’ benazepril...
- The Japanese Gazette for June contained details of the grant
of seven patent extensions, two of which were agrochemicals and
five pharmaceutical. Daiichi Pharmaceutical were granted two extensions
for levofloxacin...
- The Japanese Gazette also contained details of a further 14
extension applications. Interestingly, 9 of these were for drugs
used in the suppression of rejection in renal transplants...
- We have just received the SIBprima IP newsletter from our friends
in Societa Italiana Brevetti...
- This week in our section reporting granted EP patents we notice
the grant of EP553234. This patent assigned to Promega discloses
luciferase compositions...
- UK initial (“A0”) applications filed June 9th -
June 15th 2005
|
Week
28:
- The UK Patents and Design Journal reports the grant of 4 SPCs
this week. Protein Design Labs added to their portfolio of protection
for EP451216 with the grant of the SPC for daclizumab which expires...
- In addition to reporting the SPC for the ritonavir and lopinavir
combination (Kaletra) that we noted in Current Patents Gazette
0526, the PDJ also reports that Abbott have been granted an SPC
for adalimumab (Humira)...
- Also noted in the PDJ is the expiry of Schering Corp’s
SPC on EP57401 the product patent for mometasone furoate on June
21. Different formulations of mometasone...
- Over the last two weeks we have noticed that there have been
an unusually high number of PCT applications published without
IPC codes...
- Myriad Genetics has held onto some European patent rights for
its BRACAnalysis breast cancer risk gene tests, but continues
to attract controversy and opposition. In February, the Current
Patents Diagnostics Gazette reported that the European Patent
Office (EPO) Opposition Division had upheld Myriad’s...
- UK initial (“A0”) applications filed June 3rd _
June 9th 2005
|
Week
27:
- The UK Patents and Design Journal (PDJ) contains details of
several Supplementary Protection Certificate events. The entry
into force of Altana’s pantaoprazole SPC on 10th June extends
the protection for pantoprazole to May 2009, whilst the expiry
of the SPC for Pfizer’s nafarelin (Synarel)...
- Three SPC grants are recorded, the first two being for mycophenolate
products. The first was to Roche Palo Alto LLC (formerly Syntex)
for mycphenolate mofetil and extends the protection based on EP281713
to November 2010, corresponding to the Swiss Authorisation of
November 3rd, 1995. Interestingly, previous SPCs across Europe...
- Our attention has been drawn to some very unusual claims that
appeared on June 16th in a series of four technically related
applications from The Scripps Institute that begins with WO2005053614.
The subject of this quartet is protein kinase inhibitors based
on a distinctive indolinone template...
- UK initial (“A0”) applications filed May 27th -
June 2nd 2005
|
Week
26:
- The UK PDJ does not contain any SPC notifications this week
and no new applications have been added to the online database.
However, we have noticed that Abbott’s application for an
SPC on EP674513 for the ritonavir /lopinavir combination...
- Two weeks ago, in the Current Patents Gazette, we commented
on Roche Palo Alto LLC’s UK SPC application for palonosetron
based on EP430190. This followed the EU Marketing Authorization
of March 22nd...
- A joint application from Newron and Vicuron caused some confusion
this week. It is the first PCT application to be published naming
these companies, who work in markedly different therapeutic areas;
Newron is known to specialize in treating CNS disorders, whereas
Vicuron develop medicines for infectious diseases...
- Looking at UK initial “A0” applications this week
Arrow Therapeutics Ltd, have filed an application relating to
an apparently unreported collaboration...
- KU Leuven and the D Collen Research Foundation VZW, frequent
joint patentees in the past, are now applying for a UK patent
on the subject of autism...
- UK initial (“A0”) applications filed May 19th -
May 26th 2005
|
Week
25:
- The UK Patents and Design Jounal (PDJ), this week reports the
grant of two SPCs. The first is to Wyeth for their sirolimus (Rapamune)...
- Eli Lilly gained rather more protection with almost 2.5 years
for their SPC for drotrecogin alfa (Xigris) their treatment for
severe sepsis...
- Readers may remember that we commented in an earlier Current
Patents Gazette on the ECJ decision which confirmed the view of
the UK PTO and Luxembourg authorities that a first Approval in
Switzerland was a valid Community approval...
- Notification was also given in the PDJ of the expiry of GSK’s
antiepileptic agent, lamotrigine, which lost SPC protection May
29...
- In the course of claiming novel bombesin receptor antagonists,
BioFocus Dicovery Ltd has maybe inadvertently identified some
of its more promising lead compounds. The compounds modulate the
bombesin receptor subtype 3 (BRS-3)...
- The USPTO has rejected all the claims in Pfizer’s US5969156.
The patent claimed crystalline forms of atorvastatin...
- UK initial (“A0”) applications filed May 13th -
May 19th 2005
|
Week
24:
- This weeks UK PDJ only contains one item of SPC information,
the formal recording of the lodging of Roche’s application
for an SPC for palonosetron...
- Another new SPC application lodged in the UK recently was for
ziconotide by Elan Pharmaceuticals, although this has not yet
formally appeared in the PDJ. US approval for zirconotide, a non-opioid
analgesic
- It is unusual for us to carry information about SPCs in Iceland,
however this month’s Icelandic Gazette contains details
of an SPC granted to Hoffman La Roche for capecitabine...
- Huaibei Huike published a PCT application this week relating
to huvastatin. This is a prodrug of pravastatin...
- UK initial (“A0”) applications filed May 4th - May
11th 2005
|
Week
23:
- The UK Patents and Designs Journal (PDJ) for this week formally
records the entry into force of the SPC for levetiracetam based
on UCB’s EP162036...
- Purdue Pharma’s appeal against Endo Pharmaceuticals’
alleged infringement of the patents disclosing Purdue’s
OxyContin controlled release formulation of oxycodone has finished...
- Introgen Therapeutics announced victory last week in its opposition
of European Patent EP390323. The patent is entitled “Detection
of loss of the wild-type p53 gene”...
- UK initial (“A0”) applications filed April 29th
- May 4th 2005
|
Week
22:
- The Japanese Patent Gazette published May 25th, contained details
of 6 patent extensions, 3 plant protection (all from Bayer)...
- A five year extension was obtained by Merck Sharp & Dohme
for rizatriptan benzoate (Maxalt 10mg tablets) used in treating
migraine...
- The University of British Columbia (UBC) also gained a 5 year
extension on JP2137244 for verteporfin, which is marketed by Novartis
as Visudyne. QLT Inc...
- Two weeks ago we reported that Roche were the recipients of
the first granted Hungarian SPC for ganirelix. In fact we now
see that nine SPCs have been granted in Hungary and Roche were
the recipients of the first 3 for ganirelix, valganciclovir, and
capecitabine...
|
Week
21:
- This week’s UK PDJ reports the entry into force on May
1st, of the SPC for Pfizer’s (formerly Pharmacia’s)
ibutilide...
- A new SPC application was also observed on the UK PTO web site
for palonosetron based on Roche Palo Alto LLC’s EP430190
(formerly Syntex)...
- Astellas is the exclusive licensee of this patent and has been
marketing Adenoscan since 1995...
- Tercica announced this week that the High Court of Justice (Chancery
Division Patent Court) in London had issued rulings in their patent
infringement litigation case against Insemd and Avecia and in
the related patent revocation action...
- Amicus Therapeutics has had two PCT applications published on
treatments for Gaucher disease, the first to emerge from this
company...
|
Week
20:
- No new SPC actions were reported in this week’s UK PDJ,
but details of three new SPC applications can be found on the
Patent Office Web site. These include a request filed by NPS Pharmaceuticals
for cinacalcet...
- Roche Palo Alto LLC is the recipient of the first registered
Hungarian SPC (Registration Number S00001) for their ganirelix
product...
- The introduction of a European Paediatric exclusivity provision
moved a small step closer recently, with the production of the
European Parliament Draft Report...
- AstraZeneca has a PCT application published this week claiming
the use of sulfonamide derivatives as inhibitors of CoA:diacylglycerol
transferase (DGAT), for treating obesity and diabetes...
|
Week
19:
- This weeks UK Patents and Design Journal (PDJ) contained details
of one SPC grant and notification of three SPCs entering into
force. The Granted SPC was to Otsuka Pharmaceutical Co Ltd for
aripiprazole...
- Dow Chemical Co., not normally associated with pharmaceutical
inventions, have the SPC for Quadramet which entered into force
on the 15th April...
- Ribapharm Inc.’s SPC for ribavirin on EP643970 entered
into force April 16th and expires in April 2010. Ribvirin was
initially codeveloped by ICN Pharmaceuticals...
- Coincidentally, the April edition of the Japanese Patent Gazette,
which we have just received, contained notification that Roche’s
Japanese patent JP2980569 was granted an extension of 4 years
and 25 days for the Pegasys (peginterferon alfa 2a) 180 microgram
subcutaneous injection...
- On 29th April, GlaxoSmithKline submitted an SPC application
for the abacavir + lamivudine combination...
|
Week
18:
- The UK PDJ this week records the entry into force of 3 SPCs
for Recombinant human Factor VIII products...
- Yeda R&D Co. Ltd are reported as having withdrawn their
request for SPC/GB04/008 for a human monoclonal antibody...
- The PDJ records the filing of SPC applications to Watson Pharmaceuticals
for oxybutynin with triacetin enhancer, to Schering AG...
- Further SPC applications noted this week were to Genentech,
who have requested an SPC on EP1325932 for bevacizumab (Avastin)
and to Duke University...
- Also received this week, was the INPADOC Patent Gazette Newsletter
01/05, which contained details about a new regional grouping appearing
in the INPADOC files (and on esp@cenet)...
|
Week
17:
- The UK PDJ this week records the expiry on April 1, 2005 of
the SPC granted to Merrell Pharmaceuticals (now Sanofi-Aventis)
for fexofenadine...
- Section A has yielded a few interesting cases this week. WO2005037839
from Entomed appears to disclose the first small molecules...
- In a similar vein X-Ceptor Therapeutics have disclosed the first
small molecules...
- Array BioPharma and InterMune are both named for the first time
as joint assignees on a PCT application...
|
Week
16:
- You may have noticed the decision of the US Patent and Trademark
Office to stop publishing filing dates (§371 dates) of PCT
entries with immediate effect. This decision has generated a considerable
stir among patent information providers...
- No SPC events were reported by the UK PTO this week. However,
an important judgement was released by the European Court of Justice
(ECJ) on April 21st, regarding two SPC related cases...
- The ECJ agreed with the UK and Luxembourg authorities and the
Advocate General’s opinion, as expressed in September 2004
(see Current Patents Gazette 0446 published November 12, 2004).
In short, where a Swiss MA is the earliest approval...
- The result of this decision means that the for case C-207/03
the SPC for basiliximab expires April 6, 2013 rather than October
8 2013...
- In case C-252/03 the drug in question was Millenium Pharma’s
eptifibatide for which the Swiss authorisation was February 27,
1997...
|
Week
15:
- This weeks UK PDJ reports the expiry of the SPC awarded to Prodes
SA for aceclofenac...
- A further 5 SPC applications were noted this week, which should
be reported in the PDJ in forthcoming issues. Aventis applied
for an SPC on EP885961...
- Following on from General Hospital Corp's SPC application one
week previously, Schering also filed an SPC application on EP405704
for gadoxetic acid...
- Overactive bladder treatments were also popular this week and
included two SPC applications from Novartis for darifenacin hydrobromide.
Marketed as Enablex...
- Watson Pharmaceuticals, more known as a generic drug producer,
have requested an SPC for oxybutynin with triacetin enhancer...
- This week a court in Indianapolis upheld Eli Lilly's patent
protecting olanzapine...
|
Week
14:
- No new SPC events were reported in the UK PDJ this week, but
the March issue of the Japanese Patent Gazette contained details
of seven granted patent extensions. GSK (formerly The Wellcome
Foundation) were granted two extensions...
- Daiichi Pharmaceutical KK received extensions of 4 months 10
days on two related patents for levofloxacin...
- Novartis was granted two extensions of 2 years 8 months and
17 days for atazanavir sulphate (Reyataz ®)...
- Anticoagulatant parnaparin sodium gained 3 years 10 months and
2 days for Opocrin SPA...
- Twenty years after its invention, perhaps the most widely used
molecular biology technique in history came off-patent on Monday,
March 28th. The Polymerase Chain Reaction, or PCR...
|
Week
13:
- This weeks UK PDJ reports the grant of an SPC to AHP Manufacturing
BV on EP939121 for a recombinant TNF-R p75IgI fusion protein product...
- Yeda Research and Development Co. Ltd also received an SPC for
EP186833 a process patent for the competitive TNF related product,
adalimumab...
- General Hospital Corporation has filed for a UK SPC on EP222886
for Primovist (gadoxetic acid, disodium)...
- General Hospital Corp also had EP560928 and EP476953 revoked.
The first patent, EP560928, described an inhaler device...
|
Week
12:
- This weeks UK PDJ reports the filing of 5 SPC applications.
These applications, from Callegy Pharmaceuticals, Laboratoires
Servier, Bayer, Protein Design Labs and Schering Corp...
- Eight new SPC applications were filed in the last week. Eli
Lilly and The Trustees of Princeton University shared an SPC for
pemetrexed...
- The remaining seven SPC applications were filed in the name
of Medeva BV and were based on EP747058. These were for various
combinations of diphtheria, tetanus and pertussis...
- Pfizer have fifteen applications published this week claiming
new uses and combinations containing the vitamin D analog 2MD
licensed from Deltanoid...
|
Week
11:
- This weeks UK PDJ contains details of a number of SPC events,
the first being to McNeilabs Inc. (Johnson & Johnson) who
were granted an SPC on EP566709 for their tramadol hydrochloride
+ paracetamol combination, known as Ultracet. With generic competitors...
- It was also reported that the SPC on EP155096 entered into force
on 20 February. This gives just over 2 years additional protection
to Merck & Co...
- In a notification that reminds us of some of the quirks in gaining
SPC protection, the PDJ reports that SPC/GB04/009, protecting
AstraZeneca’s fulvestrant,...
- At the opposite end of the patent lifecycle, notification was
given that Glaxo’s SPC for ondansetron had expired on 22
February 2005. According to analysts from our Strategic Drugs
database (SDdb)...
|
Week
10:
- This weeks UK PDJ records the entry into force of the SPC previously
granted to Schering Corporation for desloratidine...
- M.L.Laboratories UK SPC for icodextrin based on GB2154469, was
also reported as entering into force...
- ZymoGenetics’ EP624095, which describes the use of factor
XIII for reducing perioperative blood loss...
- Sanofi-Aventis is suing Novopharm after Novopharm gained approval
for a generic version of the company’s Lovenox...
- Ranbaxy is putting some effort into a uro-selective alpha1-adrenoreceptor
antagonist...
- This week Natco Pharma announced the grant of EP1221947...
- Sekhsaria Chemicals Ltd has submitted a GB application on a
stable crystalline form of entacapone...
- Hunter-Fleming Ltd has also filed a GB application this application
discloses tricyclic cytoprotective compounds...
|
Week
09:
- This weeks UK PDJ reported the entry into force of the SPC
for Chiron’s humanised monoclonal antibody treatment for
breast cancer, trastuzumab...
- Five new SPC applications were announced this week, four of
which relate to pharmaceuticals. The first request by Callegy
Pharmaceuticals was for a 0.4 % concentration nitroglycerin ointment...
- The Japanese patent gazette for February contained news of 5
extensions being granted. Genzyme Corporation was granted 2 extensions...
|
Week
08:
- This week sees the announcement that Emory University has been
granted a UK SPC protecting its HIV treatment emtricitabine...
- Schering has been granted a UK SPC protecting a combination
of estradiol and drospirenone marketed as Yasmin...
- In an unusual combination of announcements, the official confirmation
that a UK SPC for omeprazole sodium has now entered into force...
- Another unusual announcement concerns an Erratum correcting
the expiry date of SPC/GB93/158 awarded to Knoll for flosequinan.
This states that the expiry date has been recalculated to 6 January
2006...
- Spectrum Pharmaceuticals has challenged a Glaxo patent protecting
its injectable sumatriptan Imitrex. Spectrum has filed a ANDA...
- Pfizer is suing Ranbaxy for infringement of a quinapril patent.
Teva has launched a product in the US...
- The University of Newcastle Upon Tyne has filed a GB A0 initial
application on stem cells. Back in August 2004, scientists at
the University were given a licence...
|
Week
07:
- This week official confirmation of the rejection of a UK SPC
application attempting to protect adalimumab was provided. This
application based on EP486526 was made by Peptech and covered
the Humira product...
- Yamanouchi has been granted a UK SPC for its muscarinic M3
antagonist solifenacin...
- Notice that an SPC has entered into force for GSK’s 5-HT
3 antagonist ondansetron was also given this week. This SPC granted
to Glaxo...
- A UK SPC protecting lercanidipine has also come into force.
This dihydropyridine calcium channel blocker for the treatment
hypertension from Recordati...
- Scotia Pharmaceutical’s UK SPC protecting a combination
of lithium succinate and zinc sulphate has now lapsed...
- A second SPC application attempting to protect duloxetine was
published this week. This application from Boehringer Ingelheim
relies on EP654264...
- Japan Tobacco and Tularik can be seen collaborating on their
second patent application disclosing diacylglcerol acyltransferase
(DGAT) inhibitors...
|
Week
06:
- This week’s Patents and Designs Journal (PDJ) from the
UK Patent Office includes a notice to the effect that Boehringer
Ingelheim has been granted a Supplementary Protection Certificate
(SPC/GB02/037) for a combination of telmisartan and hydrochlorothiazide
(HCTZ). The angiotensin II antagonist
- It is quite rare to find a patent application claiming new
compounds which can be positively linked to a candidate already
well into clinical development. However, that may be the case
with a PCT application published this week in the name of Gedeon
Richter, relating to carbamoyl cyclohexane derivatives with mixed
dopamine D2 and D3 antagonist action
|
Week
05:
- This weeks UK PDJ announces the grant of three UK SPCs assigned to both
Chiron and Novo Nordisk. All three are based on the same patent, EP466199.
They protect rurioctocog alfa, ocotocog alfa and moroctocog alfa...
- Also published in the UK PDJ this week was notice that the UK SPC protecting
Knoll’s flosequinan...
- Notification of two UK SPC applications were also published this week.
The first attempts to protect Naemis a combination of estradiol and nomegestrol
from Theramex...
- The second application is from Eli Lilly and covers its dual serotonin
and norepinephrine reuptake inhibitor duloxetine...
- A ruling by the United States Court of Appeals for the Federal circuit
against Merck & Co was given at the end of last week. After opposition
by Teva...
- DPP IV inhibitors, of which Novartis’ vildagliptin is the most advanced
in development for diabetes treatment, in the main contain a cyanopyrrolidine
moiety. GSK appears to be pursuing...
|
Week
04:
- This weeks PDJ contained no UK SPC events, however we received the Japanese
gazette for January which contained details of 4 granted patent extensions.
Three of these were awarded to Novartis who gained 4 years 1 month and 25
days extension to JP6008278 for their veterinary drug valnemulin hydrochloride
(Econor). IDEC Pharmaceutical Corp...
- An opposition division of the European Patent Office ruled that EP705902
could be maintained in an amended form. This patent is assigned to Myriad
Genetics, the University of Utah and the US Department of Health and Human
Services. The patent protects Myriads...
- This week Genaissance announced that it had obtained an exclusive license
to technology from Vanderbilt University...
- The grant of EP957914 to POZEN was announced this week. The patent covers
the company’s MT-400 technology, a combination of 5-HT agonist and NSAID...
|
Week
03:
- The UK PDJ for this week reports the entry into force on 26th December 2004
of the SPC for Boehringer Ingelheim’s anti-diabetes product, repaglinide,
based on the expiry of EP147850. This is the product patent of repaglinide
in its racemic form...
- Warner-Lambert has a PCT application published this week relating to the
isethionate salt of a specific CDK4 inhibitor first seen in WO03062236. Polymorphic
forms of this potential anticancer drug are claimed, the implication being
that Pfizer is now actively developing this candidate...
- Organon is among the other originators engaged in incremental improvements
to production technology for recognized candidates, claiming a process for
the S(+)-isomer of mirtazapine, the established antidepressant 5-HT2 antagonist
that is now in trials for insomnia. AstraZeneca is claiming a method for producing
fine crystals of budesonide...
- In addition, there is evidence of considerable innovative activity from
the manufacturers of active pharmaceutical ingredients (APIs) and generic
drug products. In Hungary, Biogal’s focus on the L-lysine salt of aztreonam
seems to represent a geographical shift for the Teva Group’s efforts
in this area, since production...
|
Week
02:
- The grant of Supplementary Protection Certificates (SPCs) to
R-Tech Ueno and Altana is reported in this week’s Patents
and Designs Journal (PDJ) from the UK Patent Office,...
- IBM is the subject of conflicting news items in this week’s
technical press. On the one hand IFI CLAIMS published its annual
ranking of US patentees, which showed IBM clearly in the lead
for 2004 with 3,277 patents issued during the year, some 67% more
than its closest rival, Matsushita Electric Industrial...
- Hospital cleaning standards have been the subject of an undignified
political row in the UK this week, focusing on allegedly increased
levels of nosocomial infections as a result of contracting-out
of cleaning services to the private sector. There is a somewhat
unexpected link with a PCT application appearing this week in
the name of Julius-Maximilians University...
|
Week
01:
- This weeks UK PDJ reported the expiry of the SPCs for leflunomide
and ebastine, both on the 12th December. Leflunomide, marketed
as Arava, is Aventis’ immunomodulatory agent approved for
the treatment of rheumatoid arthritis...
- The Japanese gazette for December contained details of 12 extensions
granted on 6 patents with a further 10 applications for extension
on another 8 patents. Amongst the pharmaceutical extensions, Boehringer
Ingelheim...
- A team from the Novartis Research Foundation has thrown its
hat into the erythropoietin ring this week, with a claim (filed
via the “paper company” IRM LLC) on polypeptide agents
that promote expression of erythropoietin...
- As evidenced in one of this week’s published PCT applications,
researchers at the University of Pennsylvania have taken one of
GSK’s protein kinase and cytokine suppression binding protein
(CSBP)/p38 inhibitors and used it to treat HIV infection...
|
